Daily Cardiology Research Analysis
Analyzed 75 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies emerged: (1) in a large prospective cohort, regular aspirin use was associated with substantially lower risk of aortic valve calcium and severe aortic stenosis among individuals with high lipoprotein(a), but not high LDL-C; (2) a robustly validated CATCH-AF score accurately stratified atrial fibrillation risk after ESUS to target long-term monitoring; (3) in a large matched cohort, left atrial appendage occlusion in AF patients with prior GI bleeding was linked to persistently lower recurrent GI bleeding risk.
Research Themes
- Precision prevention of calcific aortic valve disease guided by lipoprotein(a)
- Risk stratification for occult atrial fibrillation after ESUS to optimize monitoring
- Bleeding risk mitigation strategies in AF using left atrial appendage occlusion
Selected Articles
1. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.
In MESA, regular aspirin use was associated with markedly lower risks of incident aortic valve calcium and severe aortic stenosis among individuals with elevated Lp(a), but not among those with high LDL-C. Findings suggest a potential precision-prevention role for aspirin in persons with high Lp(a), pending confirmatory trials.
Impact: This is the first large, prospective, multi-ethnic analysis linking aspirin benefit to high Lp(a) for prevention of valve calcification/stenosis, potentially informing targeted preventive strategies.
Clinical Implications: For patients with markedly elevated Lp(a), clinicians may consider individualized discussions about low-dose aspirin for preventing calcific aortic valve disease while balancing bleeding risk, pending randomized evidence.
Key Findings
- Regular aspirin use was associated with lower incident AVC in high Lp(a): HR 0.42 (≥75 mg/dL) and 0.17 (≥100 mg/dL).
- Regular aspirin use was associated with lower severe AS risk in high Lp(a): HR 0.13 (≥50 mg/dL) and 0.02 (≥75 mg/dL).
- No association between aspirin and AVC/AS was observed in participants with elevated LDL-C.
Methodological Strengths
- Large, prospective, multi-ethnic cohort with standardized CT-based AVC assessment
- Multivariable Cox regression with stratification by Lp(a) and LDL-C; biomarkers not disclosed to participants
Limitations
- Observational design with potential residual confounding and self-reported aspirin exposure
- Low incidence of severe AS (1%) may limit precision of effect estimates
Future Directions: Randomized trials testing aspirin for prevention of AVC/AS in high Lp(a) individuals and mechanistic studies linking antifibrinolysis to valvular calcification are warranted.
BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. METHODS: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. RESULTS: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19-.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04-.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04-.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001-.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66-1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53-4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39-1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14-1.47). CONCLUSIONS: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).
2. Atrial fibrillation detection after Embolic Stroke of Undetermined Source: development and validation of the CATCH-AF score.
Among 543 ESUS patients under systematic ICM monitoring, the CATCH-AF score (age, CAD, heart failure, prior TIA/ischemic stroke) demonstrated strong discrimination (AUC 0.85) sustained over 4.5 years. High-risk patients (≥5 points) had a 19-fold higher AF detection hazard and substantially fewer AF-free days, supporting targeted rhythm monitoring.
Impact: Provides a validated, interpretable tool to prioritize long-term rhythm monitoring after ESUS, addressing resource constraints of universal ICM deployment.
Clinical Implications: Clinicians can use CATCH-AF to select ESUS patients for intensive or prolonged monitoring and to counsel patients on individualized AF detection likelihood.
Key Findings
- CATCH-AF achieved an AUC of 0.85 (95% CI 0.82–0.89), stable over 4.5 years.
- High-risk (≥5 points) patients had HR 19.2 for AF detection versus low-risk (0–2 points).
- Internal-external cross-validation across seven centers supported discrimination and calibration.
Methodological Strengths
- Systematic ICM monitoring in a consecutive ESUS cohort with time-to-event modeling
- Rigorous validation including time-dependent ROC, RMST, k-fold, and internal-external cross-validation
Limitations
- Developed in ESUS patients with access to ICM; generalizability to non-ICM settings requires external validation
- Potential unmeasured confounding and model transportability challenges across healthcare systems
Future Directions: Prospective impact studies to test whether CATCH-AF-guided monitoring improves AF detection yield, stroke prevention, and cost-effectiveness.
BackgroundEmbolic stroke of undetermined source (ESUS) accounts for up to one quarter of ischemic strokes, with occult atrial fibrillation (AF) as a key underlying cause. Implantable cardiac monitors (ICMs) markedly improve AF detection but are limited by cost and resource demands. Existing AF-prediction models show modest accuracy and lack longitudinal validation. We developed and validated the CATCH-AF score to provide a simple, clinically applicable tool for stratifying early and long-term AF risk after ESUS.MethodsWe analyzed 543 consecutive ESUS patients systematically monitored with ICMs. Variable selection used LASSO-penalized Cox regression. Model performance was assessed with time-dependent ROC curves, restricted mean survival time (RMST) analysis, and 10-fold cross-validation. To evaluate geographic generalizability, internal-external cross-validation was performed across seven participating centres, estimating discrimination and calibration for each held-out cohort. Based on the final multivariable model, a point-based score was derived including age, coronary artery disease, heart failure, and prior transient ischemic attack or ischemic stroke.ResultsDuring 1558.5 patient-years of follow-up, 118 patients (22%) developed new AF. The CATCH-AF score showed excellent discrimination (AUC 0.85, 95% CI 0.82-0.89), stable over 4.5 years (0.84-0.87). Compared with low-risk patients (0-2 points), those at high risk (≥5 points) had a 19-fold higher hazard of AF detection (HR 19.2, 95% CI 9.4-39.4; p<0.001) and 918 fewer AF-free days (95% CI -1080 to -757).ConclusionsThe CATCH-AF score provides a robust, interpretable, and easily applicable tool for predicting AF after ESUS, supporting targeted and cost-effective rhythm monitoring.
3. Recurrent Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Left Atrial Appendage Occlusion.
In a large propensity-matched cohort (n=18,518), AF patients with prior GI bleeding who underwent LAAO had consistently lower odds and hazards of recurrent GI bleeding from 3 months to 5 years compared with those without LAAO. Findings highlight a bleeding-sparing benefit beyond stroke prevention.
Impact: Addresses a key management dilemma by quantifying long-term bleeding outcomes after LAAO in AF patients prone to recurrent GI bleeding, informing procedural selection.
Clinical Implications: For AF patients with prior GI bleeding, LAAO may reduce recurrent bleeding risk and should be considered in multidisciplinary discussions when anticoagulation is problematic.
Key Findings
- After 1:1 PSM (n=9,259 per group), LAAO was associated with lower recurrent GI bleeding across all intervals up to 5 years (e.g., 3 months OR 0.84; 5 years OR 0.87).
- Kaplan–Meier analysis showed reduced hazard of recurrent GI bleeding with LAAO (HR 0.80; 95% CI 0.76–0.84; p<0.01).
- Bleeding risk reduction was durable from short-term (3 months) through long-term (5 years).
Methodological Strengths
- Large, multicenter real-world cohort with 1:1 propensity score matching
- Consistent effect across multiple time horizons with Cox and Kaplan–Meier analyses
Limitations
- Retrospective design with potential residual confounding and misclassification in administrative data
- Antithrombotic regimens and post-procedure management heterogeneity may influence bleeding outcomes
Future Directions: Prospective comparative studies or randomized trials to evaluate LAAO versus medical management focusing on bleeding, stroke, and net clinical benefit in high-bleeding-risk AF populations.
BACKGROUND: Concomitant atrial fibrillation (AF) and gastrointestinal (GI) bleeding present a clinical challenge due to recurrent bleeding risk associated with anticoagulation for AF-associated stroke prevention. Left atrial appendage occlusion (LAAO) offers an alternative stroke prevention strategy, but its impact on recurrent GI bleeding remains unknown. METHODS: This retrospective, multicenter cohort study used the TriNetX database to identify adults with AF on oral anticoagulation and a history of GI bleeding. Patients were stratified by treatment with or without LAAO. 1:1 propensity score matching (PSM) was employed. The primary outcome was recurrent GI bleeding. Cox regression analysis was used to generate hazard ratios (HRs) with 95% confidence intervals (CIs). Odds ratios (ORs) were used to evaluate effect sizes between groups. Kaplan-Meier curves were used for time-to-event analyses. RESULTS: After PSM, 9259 patients were compared in each group. Odds of recurrent GI bleeding were consistently lower in patients undergoing LAAO than without LAAO across all follow-up intervals: at 3 months (OR 0.84; 95% CI 0.78-0.91), 6 months, 1 year, 3 years, and 5 years (OR 0.87; 95% CI 0.82-0.92). Kaplan-Meier analysis demonstrated significantly lower risk of recurrent GI bleeding with LAAO (HR 0.80; 95% CI 0.76-0.84; p < 0.01). CONCLUSION: In patients with AF and prior GI bleeding, LAAO was associated with a significantly lower risk of recurrent GI bleeding at short-term and long-term time intervals.